4 results
The primary objective of this trial is to describe the safety and tolerability of prolonged exposure to cebranopadol in subjects suffering from cancer related pain
To assess the analgesic efficacy, safety, and tolerability of once daily orally administered cebranopadol in a total of 3 fixed doses (100 µg, 300 µg, and 600 µg cebranopadol) compared to placebo in subjects with moderate to severe chronic pain due…
To determine the activity (as measured by objective response rate by RECIST1.1) of monalizumab and trastuzumab in patients with metastatic HER2-positive breast cancer.
Primary • To evaluate the effects of cebranopadol and oxycodone on respiratory drive.Secondary• To evaluate the pupil response/ pupillometry following single oral doses of cebranopadol and oxycodone• To evaluate the effects of single oral doses of…